CN112533620B - 通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤 - Google Patents

通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤 Download PDF

Info

Publication number
CN112533620B
CN112533620B CN201980016785.2A CN201980016785A CN112533620B CN 112533620 B CN112533620 B CN 112533620B CN 201980016785 A CN201980016785 A CN 201980016785A CN 112533620 B CN112533620 B CN 112533620B
Authority
CN
China
Prior art keywords
inhibitor
adenovirus
cells
cdk4
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980016785.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112533620A (zh
Inventor
佩尔·松内·霍尔姆
罗曼·纳夫罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Teaching Center Technical University Of Munich
Original Assignee
Clinical Teaching Center Technical University Of Munich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Teaching Center Technical University Of Munich filed Critical Clinical Teaching Center Technical University Of Munich
Publication of CN112533620A publication Critical patent/CN112533620A/zh
Application granted granted Critical
Publication of CN112533620B publication Critical patent/CN112533620B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980016785.2A 2018-03-05 2019-03-05 通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤 Active CN112533620B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
EPEP18000210.7 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Publications (2)

Publication Number Publication Date
CN112533620A CN112533620A (zh) 2021-03-19
CN112533620B true CN112533620B (zh) 2025-03-28

Family

ID=61569019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980016785.2A Active CN112533620B (zh) 2018-03-05 2019-03-05 通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤

Country Status (13)

Country Link
US (1) US20210038661A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762004B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021517119A (cg-RX-API-DMAC7.html)
KR (2) KR20210031852A (cg-RX-API-DMAC7.html)
CN (1) CN112533620B (cg-RX-API-DMAC7.html)
AU (1) AU2019232768B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3762004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965632T3 (cg-RX-API-DMAC7.html)
FI (1) FI3762004T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064471T2 (cg-RX-API-DMAC7.html)
SG (1) SG11202007873VA (cg-RX-API-DMAC7.html)
WO (1) WO2019170283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DK4/6抑制剂在乳腺癌治疗中的研究进展;徐镇喜等;中国医药指南;第21卷(第16期);第74-76+83页 *
E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer;Juming Ma等;Digestive diseases and sciences;第54卷(第7期);第1425-1431页 *
Juming Ma等.E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer.Digestive diseases and sciences.2008,第54卷(第7期),第1425-1431页. *

Also Published As

Publication number Publication date
WO2019170283A8 (en) 2019-11-07
CA3092907A1 (en) 2019-09-12
CN112533620A (zh) 2021-03-19
AU2019232768B2 (en) 2025-12-18
HUE064471T2 (hu) 2024-03-28
EP3762004B1 (en) 2023-09-13
EP3762004A1 (en) 2021-01-13
DK3762004T3 (da) 2023-11-27
AU2019232768A1 (en) 2020-09-03
US20210038661A1 (en) 2021-02-11
SG11202007873VA (en) 2020-09-29
ES2965632T3 (es) 2024-04-16
KR20260089640A (ko) 2026-06-15
RU2020132466A (ru) 2022-04-05
JP2025013934A (ja) 2025-01-28
KR20210031852A (ko) 2021-03-23
RU2020132466A3 (cg-RX-API-DMAC7.html) 2022-04-05
WO2019170283A1 (en) 2019-09-12
FI3762004T3 (fi) 2023-12-11
JP2021517119A (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
Shimbori et al. Fibroblast growth factor‐1 attenuates TGF‐β1‐induced lung fibrosis
Wodrich et al. A capsid-encoded PPxY-motif facilitates adenovirus entry
US10046067B2 (en) Decorin gene delivery system and cancer treatment
JP2025013934A (ja) 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置
Alonso et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo
Excoffon et al. The role of the extracellular domain in the biology of the coxsackievirus and adenovirus receptor
WO2012022496A2 (en) Method for killing tumor stem cells
WO2016109649A1 (en) Methods and compositions for treating brain diseases
Holzmüller et al. YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma
Wienen et al. Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor
Mohr et al. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma
JP7834342B2 (ja) 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
RU2835886C1 (ru) Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента
EP2239325A1 (en) Virus growing in hypoxic cell or virus vector expressing gene therein
RU2811278C2 (ru) Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6
Wang et al. HSF1 overexpression enhances oncolytic effect of replicative adenovirus
Guo et al. Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate
Kankanamge et al. Nrf1 coordinates proteasome activity and autophagy to maintain cardiac proteostasis
US20100311809A1 (en) Viral vector system, a composition comprising the viral vector system and its use
Aguirre The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy
Wang et al. Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390407

TG01 Patent term adjustment